Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hollis A. Viray, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sentana-Lledo D, Viray H, Piper-Vallillo AJ, Widick P, Rangachari D, Wilson JL, Gangadharan SP, Aronovitz JA, Berman SM, VanderLaan PA, Costa DB. Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer. Lung Cancer. 2022 10; 172:124-126. PMID: 36075183; PMCID: PMC9719796.
    Citations: 1     Fields:    Translation:Humans
  2. Viray H, McDermott DF, Einstein DJ. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. Expert Rev Anticancer Ther. 2022 07; 22(7):695-702. PMID: 35698870.
    Citations:    Fields:    Translation:Humans
  3. Viray H, Rangachari D, Costa DB. Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. N Engl J Med. 2022 05 05; 386(18):1769-1770. PMID: 35507494; PMCID: PMC9766155.
    Citations:    Fields:    Translation:Humans
  4. Kobayashi IS, Viray H, Rangachari D, Kobayashi SS, Costa DB. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells. 2021 12 17; 10(12). PMID: 34944068; PMCID: PMC8700411.
    Citations:    Fields:    Translation:HumansAnimalsCells
  5. Sehgal K, Varkaris A, Viray H, VanderLaan PA, Rangachari D, Costa DB. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer. 2020 06; 8(1). PMID: 32581048.
    Citations: 5     Fields:    Translation:Humans
  6. Sehgal K, Piper-Vallillo AJ, Viray H, Khan AM, Rangachari D, Costa DB. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Precis Cancer Med. 2020 Jun; 3. PMID: 32776005; PMCID: PMC7410006.
    Citations: 7     
  7. Vasconcelos PENS, Gergis C, Viray H, Varkaris A, Fujii M, Rangachari D, VanderLaan PA, Kobayashi IS, Kobayashi SS, Costa DB. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2020 Sep; 1(3). PMID: 34104899; PMCID: PMC8183979.
    Citations: 10     
  8. Viray H, Coulter M, Li K, Lane K, Madan A, Mitchell K, Schalper K, Hoyt C, Rimm DL. Automated objective determination of percentage of malignant nuclei for mutation testing. Appl Immunohistochem Mol Morphol. 2014 May-Jun; 22(5):363-71. PMID: 24162261.
    Citations: 6     Fields:    Translation:Humans
  9. Viray H, Li K, Long TA, Vasalos P, Bridge JA, Jennings LJ, Halling KC, Hameed M, Rimm DL. A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. Arch Pathol Lab Med. 2013 Nov; 137(11):1545-9. PMID: 24168492.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  10. Viray H, Bradley WR, Schalper KA, Rimm DL, Gould Rothberg BE. Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas. Arch Pathol Lab Med. 2013 Aug; 137(8):1063-73. PMID: 23899062; PMCID: PMC3963468.
    Citations: 8     Fields:    Translation:Humans
  11. Dimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, Gould Rothberg B, Zolota V, Syrigos K, Rimm DL. Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol. 2011 Aug; 179(2):580-9. PMID: 21722621; PMCID: PMC3157192.
    Citations: 15     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Viray's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (79)
Explore
_
Co-Authors (13)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.